Real-World Impact of Switching From Insulin Glargine (Lantus(®)) to Basaglar(®) and Potential Cost Saving in a Large Public Healthcare System in Saudi Arabia

BACKGROUND: The advent of Basaglar(®), which is a biosimilar insulin glargine formulation for Lantus(®) has brought hope that it will result in similar outcomes and lower costs. However, some health practitioners raised some concerns about the therapeutic equivalence of this new biosimilar. Therefor...

Descripción completa

Detalles Bibliográficos
Autores principales: AlRuthia, Yazed, Bahari, Ohud H., Alghnam, Suliman, Alrumaih, Ali M., Asiri, Hassan, Alshammari, Mohammed, Alhowimel, Mansour, Al-Abdulkarim, Hana A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Public Health
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9234164/
https://www.ncbi.nlm.nih.gov/pubmed/35769787
http://dx.doi.org/10.3389/fpubh.2022.852721

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9234164/
https://www.ncbi.nlm.nih.gov/pubmed/35769787
http://dx.doi.org/10.3389/fpubh.2022.852721

Ejemplares similares